schizophrenia

News Story

Novartis Launches Fanapt in the U.S. for the Acute Treatment of Schizophrenia in Adults

01/11/2010

Novartis announced that Fanapt™ (iloperidone) tablets are now available for use across the US for the acute treatment of schizophrenia in adults. Fanapt is a twice-daily, oral antipsychotic, approved by the US Food and Drug Administration (FDA) in May 2009.

"Schizophrenia remains one of the most debilitating and difficult to treat mental illnesses. The launch of Fanapt is important because there is a need for alternative medications for many individuals who are suffering from this disease," said Ludwig Hantson, PhD, Head of Pharma North America, CEO, Novartis Pharmaceuticals Corporation. "In clinical trials, Fanapt was shown to be effective for the symptoms of schizophrenia. Fanapt also showed a low incidence of certain side effects, and the percentage of patients who discontinued treatment was similar to that of placebo."More »

fanapt, schizophrenia

FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder

08/14/2009

The U.S. Food and Drug Administration has approved Saphris tablets (asenapine) to treat adults with schizophrenia, a chronic, severe and disabling brain disorder, and to treat bipolar I disorder in adults, a serious psychiatric disorder that causes shifts in a person's mood, energy, and ability to function.More »

asenepine, FDA, schizophrenia, Sephris

New Injectable Suspension for the Management of Schizophrenia

08/04/2009

The FDA approved Invega Sustenna (paliperidone palmitate) extended–release injectable suspension for the acute and maintenance treatment of schizophrenia in adults. It is the first once–monthly, long–acting, injectable atypical antipsychotic approved in the U.S. for this use.More »

Invega Sustenna, paliperidone palmitate, schizophrenia
Syndicate content